Skip to main content

Table 2 Event distribution according to the studied classifications

From: The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of patients with hypertrophic cardiomyopathy at risk of sudden cardiac death

  Overall (n = 493) No endpoint (n = 470) Endpoint (n = 23) p-value
HCM Risk-SCD     0.018
 Low risk, n (%) 362 (73.4%) 351 (74.7%) 11 (47.8%)
 Intermediate risk, n (%) 66 (13.4%) 59 (12.6%) 7 (30.4%)
 High risk, n (%) 65 (13.2%) 60 (12.8%) 5 (21.7%)
 Risk at 5-years (%) 2.5 (1.7–4.1) 2.4 (1.7–4.0) 4.2 (2.4–6.0) 0.003
ACCF/AHA     0.075
 ICD not recommended, n (%) 281 (57.0%) 273 (58.1%) 8 (34.8%)
 ICD can be useful, n (%) 68 (13.8%) 62 (13.2%) 6 (26.1%)
 ICD reasonable, n (%) 144 (29.2%) 135 (28.7%) 9 (39.1%)
LGE classification     <  0.001
 0%, n (%) 102 (20.7%) 102 (21.7%) 0 (0%)
 0.1–10.0%, n (%) 285 (57.8%) 279 (59.4%) 6 (26.1%)
 10.1–19.9%, n (%) 63 (12.8%) 55 (11.7%) 8 (34.8%)
  ≥ 20%, n (%) 43 (8.7%) 34 (7.2%) 9 (39.1%)
  1. Continuous variables presented as mean ± standard deviation or median (25th – 75th percentiles) where appropriate
  2. ACCF/AHA American College of Cardiology Foundation / American Heart Association, HCM Risk-SCD hypertrophic cardiomyopathy sudden cardiac death risk tool, LGE late gadolinium enhancement